You are viewing: China Radioligand Therapy (RLT) Market analysis

The China Radioligand Therapy (RLT) Market was valued at $0 Million in 2025 and projected to reach to $23.9 Million by 2030, representing a compound annual growth rate of . China's radioligand therapy market stands at an inflection point, transitioning from early adoption to mainstream clinical practice.

China Radioligand Therapy (RLT) Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

China Radioligand Therapy (RLT) Market Trends and Insights

  • In 2025, China's RLT market was valued at $0.0 million, reflecting the nascent stage of this advanced therapeutic modality in the country.
  • By 2030, China is projected to reach a market size of $23.9 million, demonstrating substantial expansion as healthcare infrastructure and regulatory frameworks evolve to support precision oncology treatments. The transformation of China's RLT market is driven by increasing investments in nuclear medicine capabilities, growing prevalence of cancer diagnoses, and China's commitment to advancing targeted therapeutic options.
  • China's healthcare system is progressively adopting radioligand therapies for neuroendocrine tumors and prostate cancer, supported by government initiatives promoting innovation in medical technology.
  • The market growth reflects China's strategic positioning as a key player in the global RLT landscape, with domestic manufacturers and international partnerships accelerating market penetration. China's RLT market development is underpinned by rising healthcare expenditure, improved patient access to advanced diagnostics, and regulatory approvals facilitating clinical adoption.
  • As China continues to strengthen its oncology treatment portfolio, radioligand therapy is expected to gain prominence as a precision medicine solution, contributing to the broader expansion of targeted cancer therapies across the region..

Key Market Statistics

  • CAGR (2025-2030)
  • Market Size, 2025 ~USD 0 Million
  • Forecast, 2030 ~USD 23.9 Million
  • Country China

China Radioligand Therapy (RLT) Market Overview

Emerging Market Stage :

China's RLT market is in its nascent phase with a valuation of $0.0 million in 2025, representing significant untapped potential as regulatory frameworks and clinical adoption accelerate across the country.

Explosive Growth Trajectory :

China's market is projected to reach $23.9 million by 2030, demonstrating a remarkable expansion driven by increasing cancer prevalence, government healthcare investments, and growing adoption of precision medicine therapies.

Regulatory Advancement :

China's NMPA has begun approving radioligand therapies, with enhanced pathways for innovative oncology treatments accelerating market entry and clinical implementation across major healthcare institutions.

Healthcare Infrastructure Investment :

Significant government funding for nuclear medicine centers and radiopharmaceutical manufacturing capabilities in China is establishing the foundational infrastructure necessary for RLT market expansion.

China Radioligand Therapy (RLT) Market Dynamics

  • The market's projected growth from $0.0 million in 2025 to $23.9 million by 2030 reflects China's commitment to advancing precision oncology treatments and modernizing its healthcare delivery system.
  • Government initiatives promoting domestic radiopharmaceutical production and regulatory streamlining are accelerating market penetration. Key drivers include rising cancer incidence, increasing healthcare expenditure, and growing physician awareness of RLT efficacy.
  • However, challenges such as limited nuclear medicine expertise, manufacturing capacity constraints, and reimbursement uncertainties remain.
  • Strategic partnerships between international manufacturers and Chinese institutions are expected to facilitate technology transfer and market development, positioning China as a significant growth engine within the Asia Pacific RLT landscape..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Pharmaceuticals

    Top Technologies
    • Bioreactors
    • Analytical Testing
    • Bioanalytical Testing Services
    • Cell Counters
    • Data Management Services
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • SANOFI
    • Pfizer Inc.
    • NOVARTIS

      Key Takeaways

      • China's RLT market is projected to reach $23.9 million by 2030, starting from a baseline of $0.0 million in 2025, indicating rapid market emergence and adoption.
      • China is investing heavily in nuclear medicine infrastructure and regulatory frameworks to support radioligand therapy commercialization and clinical deployment.
      • Growing cancer incidence and government support for precision oncology are primary catalysts driving China's RLT market expansion through 2030.
      • China's RLT market represents a significant growth opportunity within Asia Pacific, positioning the country as an emerging hub for advanced targeted cancer therapies.

      Radioligand Therapy (RLT) Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment [LU-177]-PNT2002 (Product)
      Forecast Period 2025-2030
      Growth Rate CAGR of 13.2% from 2025 to 2030
      Largest Segment PROSTATE CANCER (Indication)
      Market Size Base Year (Billions) ~USD 3.16 (2025)
      Revenue Forecast (Billions) ~USD 5.87 (2030)
      Segments Covered Product, Target, Indication, End User

      China Radioligand Therapy (RLT) Market Report Segmentation

      4 segment dimensions are covered across the global market.

      By Product

      • 225Ac-Psma-617
      • 67Cusarbispsma
      • [Lu-177]-Pnt2002
      • Alphamedix (²¹²Pb-Dotamtate)
      • Alphamedix(²¹²Pb-Dotamtate)
      • Fpi-2265
      • I-131-1095
      • Lutetium-177 Dotatate
      • Lutetium-177 Dotatate (Lutathera)
      • Lutetium177 Vipivotide Tetraxetan
      • Lutetium177 Vipivotide Tetraxetan (Pluvicto)
      • Other Products
      • Radium-223 Dichloride
      • Radium-223 Dichloride (Xofigo)
      • Tlx591 (177Lu Rosopatamab Tetraxetan)

      By Target

      • Other Indications
      • Other Targets
      • Prostate-Specific Membrane Antigen (Psma)
      • Somatostatin Receptor (Sstr)

      By Indication

      • Neuroendocrine Tumor
      • Neuroendocrine Tumors (Nets)
      • Other Indications
      • Prostate Cancer

      By End User

      • Other End Users
      • Specialized Nuclear Medicine Centers
      • Tertiary Care Academic/ Comprehensive Cancer Centers

      CHINA: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035

      Segment2023202420252026202720282035CAGR (%)
      OTHER END USERS3.191.811.749.5213.6817.0661.4442.8
      SPECIALIZED NUCLEAR MEDICINE CENTERS4.292.452.371318.7723.5187.2643.4
      TERTIARY CARE ACADEMIC/ COMPREHENSIVE CANCER CENTERS9.845.495.1927.8639.3348.2153.4840.3
      TOTAL17.329.769.3150.3871.7888.77302.1841.6

      Target Audience

      • Pharmaceutical Manufacturers : Evaluate market entry opportunities, licensing partnerships, and manufacturing joint ventures to capitalize on China's projected RLT market growth and establish regional manufacturing hubs.
      • Healthcare Investors : Assess investment potential in Chinese nuclear medicine centers, radiopharmaceutical companies, and healthcare infrastructure projects supporting RLT market development.
      • Medical Device Companies : Identify opportunities for imaging equipment, diagnostic tools, and therapeutic delivery systems aligned with China's expanding precision oncology and nuclear medicine capabilities.
      • Healthcare Policy Makers : Understand market trends and international best practices to inform regulatory frameworks, reimbursement policies, and healthcare infrastructure investments in radioligand therapy.
      • Clinical Institutions : Gain insights into treatment adoption trends, patient populations, clinical outcomes, and technology requirements to guide RLT program development and resource planning in China.

      Reasons to Buy this Report

      • Early Market Entry Intelligence : Gain competitive advantage by understanding China's RLT market dynamics before major competitors establish dominance, enabling strategic positioning in this high-growth emerging market.
      • Regulatory Pathway Clarity : Comprehensive analysis of NMPA approval processes, clinical trial requirements, and reimbursement mechanisms specific to China's healthcare system for radioligand therapies.
      • Investment Decision Support : Detailed market sizing and growth projections through 2030 provide quantitative foundation for capital allocation, partnership evaluation, and market entry strategy development in China.
      • Competitive Landscape Mapping : Identify key Chinese and international players, manufacturing capabilities, distribution networks, and partnership opportunities within China's emerging RLT ecosystem.
      • Risk Mitigation Framework : Understand market barriers including manufacturing constraints, reimbursement challenges, and regulatory uncertainties to develop robust go-to-market strategies for China operations.

      Frequently asked questions

      What is the projected market size of radioligand therapy in China by 2030?

      China's RLT market is projected to reach $23.9 million by 2030, up from $0.0 million in 2025, reflecting rapid market development and adoption of this precision oncology approach.

      What are the primary drivers of RLT market growth in China?

      Key growth drivers in China include increasing cancer prevalence, government investments in nuclear medicine infrastructure, regulatory approvals for advanced therapies, and rising healthcare expenditure supporting precision oncology adoption.

      Which cancer types are driving radioligand therapy adoption in China?

      China's RLT market is primarily driven by adoption in neuroendocrine tumors and prostate cancer, where radioligand therapies offer targeted treatment options aligned with China's precision medicine strategy.

      How does China's RLT market compare to the global market?

      While China's RLT market is emerging with a projected 2030 size of $23.9 million, the global market is significantly larger at $10.91 billion, indicating substantial growth potential as China expands market penetration.

      What regulatory developments are supporting RLT adoption in China?

      China's regulatory framework is evolving to facilitate radioligand therapy approvals and clinical adoption, supported by government initiatives promoting innovation in medical technology and precision oncology treatments.

      RESEARCH METHODOLOGY

      This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global radioligand therapy market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

      Secondary Research

      Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the radioligand therapy market. The secondary sources used for this study include World Health Organization (WHO), National Institutes of Health (NIH), National Cancer Institute (NCI), US Food and Drug Administration (FDA), European Medicines Agency (EMA), and Centers for Drug Evaluation and Research (CDER), International Society for Pharmaceutical Engineering (ISPE), Innovative Medicines Initiative (IMI), Society of Nuclear Medicine and Molecular Imaging (SNMMI), European Association of Nuclear Medicine (EANM), PubMed, National Center for Biotechnology Information (NCBI), International Trade Centre (ITC), Press Releases, Company Websites, and Magazines & Proprietary Databases. Secondary sources include corporate and regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; trade, business, and professional associations; and MarketsandMarkets Analysis.

      Primary Research

      A comprehensive primary research was undertaken following an initial assessment of the global radioligand therapy market landscape through secondary research. This involved conducting in-depth interviews with market experts from the demand side, including stakeholders from pharmaceutical and biotechnology firms, CROs, CMOs, and academic and research institutions. Additionally, interviews were held with key supply-side participants, such as C-suite and senior executives, product managers, and marketing and sales leaders from prominent manufacturers, distributors, and channel partners. The research covered six major geographical regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% of the primary interviews were conducted with supply-side participants, while 30% involved demand-side experts. Data collection methods included structured questionnaires, email correspondence, online surveys, personal interviews, and telephonic discussions to understand the market dynamics comprehensively.

      The following is a breakdown of the primary respondents:

      Radioligand Therapy Market Size, and Share

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      Both bottom-up and top-down approaches were used to estimate and validate the total size of the radioligand therapy market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

      • A list of the major global players operating in the radioligand therapy market was generated.
      • The revenues generated from their radioligand therapy product have been determined through annual reports and secondary sources (including paid databases)
      • The products were mapped according to the segments of the market. Percentage shares and splits were determined based on the revenue contributed to each segment. This was verified using secondary sources and by industry experts.
      • All assumptions, approaches, and individual shares/revenue estimates were validated through expert interviews.

      Radioligand Therapy Market : Top-Down and Bottom-Up Approach

      Radioligand Therapy Market Top Down and Bottom Up Approach

      Data Triangulation

      After arriving at the market size from the estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

      Market Definition

      Radioligand therapy (RLT) is a form of precision oncology that delivers targeted radiation to cancer cells while minimizing damage to healthy cells. Once administered, the ligand guides the radioactive payload directly to cancer cells, allowing for precise radiation delivery while minimizing damage to surrounding healthy tissues.

      Stakeholders

      • Pharmaceutical Companies
      • National and Regional Research Boards & Organizations
      • Research & Development Companies
      • Contract Research Organizations (CROs)
      • Contract Manufacturing Organizations (CMOs)
      • Contract Research Development & Manufacturing Organizations (CRDMOs)
      • Medical Device Companies
      • Biotechnology Companies
      • Research Laboratories & Academic Institutes
      • Market Research & Consulting Firms
      • Regulatory Bodies

      Report Objectives

      • To define, describe, and forecast the radioligand therapy market based on product, target, indication, end user, and region
      • To provide detailed information on the significant factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
      • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the radioligand therapy market
      • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments concerning six regions—North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To profile the key players in the global radioligand therapy market and comprehensively analyze their product portfolios, market positions, and core competencies
      • To track and analyze competitive developments such as product approvals & launches, expansions, agreements, and collaborations in the radioligand therapy market
      • To benchmark players within the radioligand therapy market using the company evaluation matrix framework, which analyzes market players based on various parameters within the broad categories of business and service strategy

       

      Get the Full Radioligand Therapy (RLT) Market Report

      Full forecast, segment splits, and company analysis for all Radioligand Therapy (RLT) Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status